FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer

Share:

FDA Drug Information Updates

FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer

Science

FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer. Released July 28, 2017